Abramson Cancer Center at University of Pennsylvania (Data Collection Only)
Welcome,         Profile    Billing    Logout  
 9 Trials 
6 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Alison
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/26
07/26
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
133
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Alison
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT03179930: Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

Active, not recruiting
2
47
US
Entinostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Syndax Pharmaceuticals
Lymphoma, Relapsed, Refractory
06/25
06/25
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/26
07/26
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
SGNTGT-001, NCT04254107: A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

Terminated
1
133
Europe, Canada, US
SEA-TGT, SGN-TGT, sasanlimab, brentuximab vedotin, Adcetris
Seagen Inc.
Non-small Cell Lung Cancer, Gastric Carcinoma, Gastroesophageal Junction Carcinoma, Classical Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Cutaneous Melanoma, Head and Neck Squamous Cell Carcinoma, Bladder Cancer, Ovarian Cancer, Triple Negative Breast Cancer, Cervical Cancer
12/23
12/23

Download Options